鱼跃医疗通过了ISO13485:2003国际医疗器械质量管理体系认证 新产品十足给力 获两大券商力荐
Diving medical adopted the ISO13485: 2003 international medical equipment quality management system certification of new products very awesome won two major securities recommended
鱼跃医疗的新产品空气净化器、血糖仪将在明年一季度上市。公司对这两个品种做足了准备工作，对产品上市后的推广有详实的计划。经券商测算空气净化器在中国的市场空间超过30亿元，产品归属于医疗器械，面临较小的
Diving medical new product air purifier, blood glucose meter in the first quarter of next year listing. Of the two varieties of the preparations for the work, after the product appears on the market promotion has a detailed plan. The calculation of air purifier in the Chinese securities market space of more than 3000000000 Yuan, the product belongs to medical equipment, small faces
　鱼跃医疗主要经营医疗器械、保健用品的制造与销售,金属材料的销售。经营本企业自产产品的出口业务和本企业所需的机械设备、零配件、原辅材料的进口业务,但国家限定公司经营或禁止进出口的商品及技术除外。公司的质量体系及多种产品通过了ISO13485:2003国际医疗器械质量管理体系认证和欧盟CE认证、美国FDA认证、日本SG认证，获得了参与国际竞争的通行证。
Diving medical mainly engaged in medical equipment, health supplies manufacturing and sales, sales of metal material. Operation of the enterprise self-produced products export business and the business requirements of the mechanical equipment, spare parts, raw and auxiliary materials import business, but the state limit or prohibit the import and export of goods and technology. The company's quality system and a variety of products through the ISO13485: 2003 international medical equipment quality management system certification and the European CE certification, American FDA certification, the SG certification, obtained the permit to participate in international competition.
相关公司股票走势
Related company stock trend
广发证券21.03+0.522.54%鱼跃医疗19.13-0.68-3.43%竞争压力，同时公司可以利用制氧机的渠道迅速铺货，明年销售额有望超过5，000万元；血糖仪试纸的市场规模超过7亿元，公司的产品价格定位略高于国内产品，明年销售额约为2，800万元。
GF Securities 21.03+0.522.54% diving medical 19.13-0.68-3.43% competition pressure, at the same time the company can use the oxygen making machine in the rapid distribution channels, sales next year is expected to exceed 50000000 yuan; blood glucose meter test market size more than 700000000 yuan, the company's product price slightly higher than the domestic products, sales of about 28000000 yuan next year.
　　高盛高华证券与广发证券盘中发布研究报告，均对鱼跃医疗给出了买入评级，高盛高华证券给出了31.50元的目标价，对比鱼跃医疗目前21.08元的目标价有48.51%的涨幅，建议投资者关注该股票。
Gao Hua securities and securities trading at Goldman Sachs released research report, both on diving medical gives a buy rating, Goldman Sachs Gao Hua securities gives the target price of 31.50 yuan, in contrast to diving medical the target price of 21.08 yuan 48.51% increase, investors concerned about the stock.
　　高盛高华在研究报告中指出，我们将鱼跃医疗（002223）加入到强力买入名单。市场对公司的快速增长能否持续产生分歧，特别是在公司第三季度主营业务净利润同比负增长后，更多的投资者开始担心公司未来 2年的增长。我们认为公司 50%以上的净利润高速增长时代也许已经过去，但对公司的前景依然乐观:1）我们预测 2011-13年公司收入和净利润的复合增长率将为 33%和37%；2）空气净化器、血糖仪和无菌注射器等新产品销售情况很有可能超过我们的预期；3）如果高值耗材业务的进展踏上正轨，公司仍有可能维持在 50%以上的增长率。在医药行业降价等政策风险下，鱼跃医疗将是快速增长公司中很好的避险标的。
Goldman Sachs Gao Hua in a research note, we will dive medical ( 002223) joined to a strong buy list. The market for the company's rapid growth can continue to produce differences, especially in the third quarter of the company main business net profit year-on-year negative growth, more and more investors began to worry about the next 2 years the company's growth. We believe that more than 50% of the company's net profit growth of age may be over, but the company still optimistic about the future: 1) we forecast 2011-13 years of the company's revenue and net profit compound growth rate will be 33% and 37%; 2) air purifier, blood glucose meter and sterile syringes and other new products sales situation is likely more than us expected; 3) if the high value consumables business progress to set foot on the right track, the company could still be maintained at more than 50% growth rate. In the pharmaceutical industry such as price policy risk, diving medical will be rapid growth the company in good hedge target.
　　广发证券在研究报告中指出，明年业绩超预期取决于新产品的推广和外延性的并购 1、预计制氧机明年增速为40%以上;电子血压计增速50%;老产品15~30%的稳健增长。 2、新产品推出集中在春节后,短期会增高销售费用空气净化器:具有净化空气和消毒灭菌双重功效,又拥有医疗器械注册证,目前市场上还没有类似的产品。我们认为有望做大、成为公司又一个明星品种,带领公司走上新一轮快速增长的轨道。预计明年春节后正式推广。 血糖仪:公司在技术和销售方面都做了储备,未来有望成为中国内资的第一品牌。 3、外延性并购:我们预计未来并购仍将围绕高值耗材领域,从而丰富相应的产品线。我们看好医疗器械行业未来的发展空间,公司质地优秀,内涵外延发展均有亮点,仍旧是我们最看好的医疗器械公司之一,维持买入评级。
GF Securities in the study pointed out that next year, achievement ultra anticipated depends on the promotion of new products and the extension of the M & M 1, is expected next year growth of more than 40% oxygen making machine; electronic sphygmomanometer growth 50%; 15 ~ 30% of the old product of steady growth. In 2, the introduction of new products focus on after the Spring Festival, the short-term will increase cost of sales: air purifier with air purifying and sterilizing the dual effect, and has medical equipment registration card, currently on the market has no similar products. We expected to do big, become the company has a star variety, lead the company embarked on a new round of rapid growth track. After the Spring Festival next year is expected to officially promote. Blood Glucose Meter Companies in technology and marketing: do reserve, the future is expected to become the first brand of Chinese domestic. In 3, extension of the M & A: we anticipate future mergers and acquisitions will remain around the high value consumable field, thereby enriching the product line. We are optimistic about the medical instrument industry in the future development of space, the company excellent quality, connotation and extension development of window, is still our most valued medical equipment companies, maintain buy.
　　鱼跃医疗主要经营医疗器械、保健用品的制造与销售,金属材料的销售。经营本企业自产产品的出口业务和本企业所需的机械设备、零配件、原辅材料的进口业务,但国家限定公司经营或禁止进出口的商品及技术除外。公司的质量体系及多种产品通过了ISO13485:2003国际医疗器械质量管理体系认证和欧盟CE认证、美国FDA认证、日本SG认证，获得了参与国际竞争的通行证。
Diving medical mainly engaged in medical equipment, health supplies manufacturing and sales, sales of metal material. Operation of the enterprise self-produced products export business and the business requirements of the mechanical equipment, spare parts, raw and auxiliary materials import business, but the state limit or prohibit the import and export of goods and technology. The company's quality system and a variety of products through the ISO13485: 2003 international medical equipment quality management system certification and the European CE certification, American FDA certification, the SG certification, obtained the permit to participate in international competition.
　　"搜狐金罗盘券商研究能力评测（点击查看）"是搜狐独家开发的研报准确度评测系统，囊括所有主流券商研报数据，采用最先进的数据挖掘分析算法真实揭示券商研报准确率，是目前最具权威的券商研究能力评价体系。投资者可以参照该评测数据，长期跟踪了解券商研究能力状况，为投资提供参考。
" Sohu the Golden Compass brokerage research capacity evaluation ( see )" is Sohu exclusive development research report accuracy evaluation system, including all major securities research report data, using the most advanced data mining analysis algorithm real reveal Securities Research Report accuracy, is currently the most authoritative brokerage research ability evaluation system. Investors can refer to the evaluation data, long-term tracking of understanding securities research ability, provide reference for investment.